Shenzhen, China, April 16, 2013 - BGI Health and ACIBADEM Healthcare Group Genetic Diagnostic Center in cooperation with Genoks Company Molecular Biology, signed a Memorandum of Understanding (MoU) for jointly introducing the advanced genetic testing technologies to Turkey and improving Turkish reproductive healthcare. This partnership will foster the applications of genetic testing technologies in the areas of Monogenic disorders, personalized medical healthcare, birth defects that cause terrible diseases, among others.
With the fast development of scientific technologies, there are a variety of testing tools that parents can use to look into their baby's future health, or to predict some of most serious hereditary diseases. Among them, genetic testing is the latest and most sophisticated of techniques used to detect gene variants associated with a specific disease or condition. In the clinical applications, genetic testing technologies can be performed to confirm a suspected diagnosis, to predict the possibility of future illness, to detect the presence of a carrier state in unaffected individuals (whose children may be at risk), and to predict response to therapy.
Considering the potential and importance of genetic testing, ACIBADEM Healthcare Group Genetic Diagnostic Center and BGI Health entered collaboration for further accelerating its clinical applications, and benefiting the reproductive health of Turkish population. This partnership will combine BGI Health's powerful genetic testing platform and genomic knowledge with Acibadem hospital's splendid clinical expertise and experience. The collaboration will involve Non-invasive Fetal Trisomy testing (NIFTY), Monogenic disorder genetic testing, Exome-seq based personalized medical healthcare, HLA genotyping, among others.
"Through the powerful combination of complementary advantages, the cooperation between BGI and ACIBADEM Healthcare Group Genetic Diagnostic Center will be con
|Contact: Jia Liu|